HRT Contraindications: Who Should Not Take Hormone Replacement Therapy?

What are the main HRT contraindications?

The main contraindications to systemic menopause HRT are unexplained vaginal bleeding, active or severe liver disease, a history of breast cancer or another estrogen-sensitive cancer, a history of stroke, heart attack, or coronary heart disease, a history of blood clots (DVT, PE, or VTE), a known high-risk clotting disorder, and pregnancy. Major bodies including the FDA, the American College of Obstetricians and Gynecologists (ACOG), and The Menopause Society list these as reasons to avoid systemic hormones — or to get specialist review — before starting.

Let's keep it plain. “Systemic” just means medicine that travels through your whole body — pills, patches, gels, sprays, and some rings. These are the contraindications that matter most for systemic HRT:

• Unexplained vaginal bleeding(bleeding that hasn't been checked out yet)
• A history of breast cancer — of any type — or another cancer that can be fed by estrogen
• Endometrial (uterine) cancer, or thickening of the uterine lining that hasn't been treated
• A history of blood clots — DVT (a clot in a deep vein, usually a leg), PE (a clot that travels to the lungs), or VTE (the umbrella term for both)
• A known clotting disorder (for example, Factor V Leiden — an inherited condition that makes clots more likely)
• A history of stroke, heart attack, or coronary heart disease
• Active or severe liver disease
• Pregnancy, or the chance you might be pregnant
• A serious allergy to the ingredients in a specific product

One thing to hold onto: every item above is a systemic concern. Low-dose vaginalestrogen — used only for vaginal and urinary symptoms — is handled differently, because very little of it reaches your bloodstream. That doesn't make it a free pass, and we'll get to the details. But mixing up “whole-body HRT” with “low-dose vaginal estrogen” is the single most common mistake we see, so keep them separate in your head.

Why each red flag is on the list

You don't have to take our word for it — here's the why behind each one, in a line:

• Unexplained bleeding can be a sign of something that needs a diagnosis first. Adding hormones can muddy the picture.
• Estrogen-sensitive cancerscan be fed by estrogen. That's the whole reason these are hard stops for systemic hormones.
• Clots, stroke, and heart attacks are about your blood and blood vessels. Some forms of estrogen nudge your clotting risk up.
• Liver disease matters because your liver helps process hormones, especially the pill form.
• An intact uterus plus estrogen alone raises the risk of uterine cancer — which is why a second hormone is usually added (more below).

Is it a hard “no,” or just a reason to change the type of HRT?

Some histories are usually a hard stop for routine systemic HRT, while others are risk modifiersthat change the route, the dose, the monitoring plan, or the treatment choice. The biggest error is treating every concern as either “HRT is forbidden” or “HRT is totally safe now.” The Menopause Society's guidance is built on personalizing by age, timing, route, dose, and regular re-checks — not one-size-fits-all.

Think of it as three buckets:

Here's our one honest admission, and we'd rather say it out loud: online HRT is not the right starting point for everyone. If your history includes certain cancers, clots, a stroke, a heart attack, unexplained bleeding, or serious liver disease, the safest next step is a real evaluation — sometimes with a specialist — beforeany prescription. A clinic that would hand you hormones in five minutes flat without asking about those things isn't being convenient. It's being careless.

And that's exactly why you can trust the rest of this page. We're not here to push you. We're here to help you find out where you stand — and most people worried about contraindications land in the yellow or green, not the red. If you're in the red, we'll point you to the right door, not a checkout button.

Does the type or route of HRT change whether it's safe for you?

Often, yes — and this is the detail that turns a lot of “no” answers into “maybe.” Oral estrogen (the pill) passes through your liver first, which raises clotting proteins, so it carries more clot risk. Patches, gels, and sprays (called transdermal) skip that first pass. In a 2015 review of 15 studies published in the Journal of Clinical Endocrinology & Metabolism, the pill was linked to about 1.6× the risk of a first blood clot, and about 2× the risk of a DVT, compared with the patch (real-world observational data, not a perfect trial). Low-dose vaginal estrogen barely enters the bloodstream at all. So the question is rarely just “HRT: yes or no.” It's “which route, at what dose, for myhistory.”

This is the part almost no consumer page assembles in one place, so we did. Read each row as a starting point for a conversation — not a green light. Your clinician makes the call, and product-specific labels still apply.

How your history maps to each route

Key: Avoid = generally not used  ·  Ask= sometimes an option with specialist judgment  ·  Often lower clot risk = generally the gentler route on clotting, still a clinical decision.

The patch's clot advantage is well supported. On stroke, the picture is more about dose and your overall risk, so ACOG notes oral estrogen may raise clotting while the patch has little or no such effect — and lower-dose or transdermal routes may ease stroke-risk concerns for some people. The takeaway is the same: if you're in the “yellow light” group, you're not choosing between HRT and nothing. You're choosing the formthat fits your body — and that's a clinician's job, with your full history in front of them.

Verified June 15, 2026 (from Midi's website): Midi is available in all 50 states and is in-network with most PPO plans — coverage varies by plan, so deductibles and copays may still apply. Midi is not enrolled with Medicaid or Medi-Cal and cannot treat those patients even as self-pay; it is notcovered by Medicare (Medicare beneficiaries can be seen as self-pay but can't submit claims). Before choosing any provider, confirm whether the medication offered is FDA-approved, compounded, or both.

Affiliate link — The HRT Index is an independent comparison resource for HRT telehealth providers, and we may earn a commission. We list Midi for its clinician screening and insurance fit, not because it's right for everyone.

Can you take HRT if you've had breast cancer or another hormone-sensitive cancer?

A personal history of breast cancer is one of the strongest reasons not to start systemic HRT casually or through a quick online intake. Exceptions exist only after an individualized risk-benefit talk that usually involves your oncologist. If this is you, your next step is specialist review — not a provider sign-up button.

We want to answer the question people actually type, which is usually not “is HRT risky in general?” It's “does my mom's breast cancer mean I can't take HRT?” or “I had breast cancer years ago — am I out of options?” Those are two very different situations.

Your own history is not the same as your family's

• A personal history of a hormone-sensitive cancer is a major red flag for whole-body estrogen.
• A family history is a risk factor to discuss — it raises your baseline risk and shapes the conversation, but it is not the same as having had the cancer yourself. Many women with a family history still explore HRT safely after a proper risk review.
• BRCA gene carriersor anyone who's had risk-reducing surgery need specialist nuance. Don't guess — ask.

What about vaginal estrogen after breast cancer?

This one is genuinely unsettled, so here's the honest version. Low-dose vaginal estrogen has minimal systemic absorption, and current evidence has not shown a clear increase in cancer recurrence for survivors who are on tamoxifen or not on hormone-blocking therapy. For survivors on aromatase inhibitors(a common type of hormone-blocking drug), it's more debated, and most clinicians approach it cautiously — so this is a decision to make with your oncologist, not online. There are also non-estrogen options for vaginal symptoms, which we cover below.

What to ask your clinician

• Was my cancer hormone-receptor positive?
• Should my oncologist be part of this decision?
• Is systemic HRT off the table for me — or just certain forms?
• If my symptoms are vaginal or urinary only, is local therapy a separate conversation?

No provider button here on purpose. This is a specialist conversation. Read next: HRT and breast cancer risk.

Can you take HRT if you've had a blood clot, stroke, or heart attack?

A history of DVT, PE, VTE, stroke, heart attack, coronary heart disease, or a high-risk clotting disorder is a strong reason to avoid routine systemic HRT unless a clinician decides otherwise. The route can matter — the patch carries less clot risk than the pill — but a clotting or cardiovascular history is never a do-it-yourself, start-it-online decision.

The clot terms, decoded

• DVT — deep vein thrombosis, a clot in a deep vein (often the leg)
• PE — pulmonary embolism, a clot that has traveled to the lungs
• VTE — venous thromboembolism, the umbrella word for both

If you've had any of these, or you carry an inherited clotting disorder, this needs a clinician's eyes before any hormone.

Pill vs. patch, honestly

The Menopause Society points out that transdermal (patch/gel) routes and lower doses may carry less risk of clots than oral estrogen, because they skip the liver's first pass. That's real, and it's why someone told “no” to the pill sometimes hears “maybe” about a patch.

But here's the line we won't cross: patches are not “safe for everyone.” A lower risk is not zero risk. If clots are in your history, the right framing is: “Should I avoid oral estrogen entirely, and would a patch, a local treatment, or a non-hormonal option be safer for me?” — asked to a clinician who knows your records.

Can you take HRT if you have unexplained bleeding, a uterus, or endometrial risk?

Unexplained vaginal bleeding should be evaluated before starting HRT, because bleeding can signal something that needs a diagnosis first, and hormones can complicate the picture. And if you still have a uterus, estrogen alone usually isn't the path — “unopposed” estrogen (estrogen without a second hormone) can thicken the uterine lining and raise the risk of uterine cancer, so clinicians add a progestogen to protect it.

Bleeding gets checked first — every time

New or unexplained bleeding is one of the clearest “pause and get evaluated” signals on the whole list. It usually turns out to be something manageable, but it needs a look before hormones enter the chat.

Estrogen alone vs. estrogen + a second hormone

“Progestogen” just means progesterone or a progesterone-like medicine that protects the lining of your uterus.

What the 2026 FDA change did not touch here

When the FDA updated HRT labels in 2025–26, it removed several warnings from the boxed warning — but it specifically kept the endometrial (uterine) cancer warning on systemic estrogen-aloneproducts for women with a uterus. So the “you need uterine protection” rule still stands. More on the full FDA change next. (Read next: the FDA black box warning change and the 2026 HRT label changes.)

Can you take HRT with liver disease, high blood pressure, migraines, diabetes, or gallbladder issues?

Some of these are contraindications and some are just risk modifiers. Active or severe liver disease is a serious concern; controlled blood pressure, treated diabetes, migraines, or a gallbladder history more often change the route, the dose, or the monitoring plan than rule HRT out entirely. As Mayo Clinic notes, HRT risk depends on the type, route, dose, duration, your age, and your personal health — not a single yes/no.

A quick run-through:

• Active liver disease — not an online-start situation. Severe active liver disease is a contraindication for systemic HRT. Ask whether any hormone option is appropriate for you.
• High blood pressure — uncontrolled or severe high blood pressure (around 180/110 or higher) should be addressed first, because of a possible stroke-risk concern, per a cardiovascular review in Circulation. Controlled blood pressure is often workable with clinician review.
• Migraine with aura— treat it as a route conversation. Auras come with a stroke-risk consideration, so lower-dose or patch options often come up. Don't accept a blanket “it's fine.”
• Diabetes, higher body weight, high cholesterol, smoking — these raise your baseline clot and heart risk. Disclose them. They may steer the route choice and how closely you're monitored.
• Gallbladder disease — Cleveland Clinic lists gallbladder and liver disease among HRT cautions; the pill form is the bigger concern, so route can matter here too.

None of these belongs on a “never” list by itself. They belong on your intake form, so a clinician can choose the safest plan.

Is being over 60 or more than 10 years past menopause an HRT contraindication?

No — not by itself. Age and timing are a risk-benefit factor, not the same thing as a breast cancer, clot, stroke, heart attack, liver disease, pregnancy, or unexplained-bleeding contraindication. They change how carefully a clinician weighs systemic HRT, the route, the dose, and whether non-hormonal or local options make more sense.

The FDA's 2026 update points to timing: starting HRT before age 60, or within 10 years of menopause, generally has a more favorable risk-benefit balance. That doesn't mean a hard cutoff at a certain birthday. ACOG also advises against routinely stopping systemic estrogen just because someone turns 65 — the decision stays individual.

So if you're past 60, or more than a decade past your last period, you're not automatically disqualified. You're in the “needs a careful, personal conversation” group — about whether to start, which route, and what dose, weighed against your symptoms and your other risks.

What should a good online HRT provider ask before prescribing?

A responsible online HRT provider should ask enough medical-history questions to catch contraindications and route-specific risks before prescribing anything — including your cancer history, clot and heart history, liver health, pregnancy status, whether you still have a uterus, your current medications, and whether your symptoms even need systemic treatment. If an intake skips these, that's a trust problem, not a time-saver.

The safety questions a good intake covers

A solid menopause intake asks about:

• Your age and how long since your last period
• Whether you've had a hysterectomy (uterus status)
• Any unexplained bleeding
• Personal history of breast, uterine, or other hormone-sensitive cancer
• Any clots (DVT/PE/VTE), or a known clotting disorder
• Any stroke, heart attack, or heart disease
• Liver disease or abnormal liver tests
• Pregnancy or breastfeeding
• Blood pressure, migraines (with or without aura), and smoking
• Your current medications and any past HRT side effects
• What your main symptoms actually are — and whether they're whole-body or vaginal-only

Red flags of a provider to walk away from

• Promises HRT is safe for everyone
• Treats compounded hormones as automatically safer
• Doesn't ask about cancer, clot, stroke, or liver history
• Doesn't ask whether you still have a uterus
• Pushes hormones for disease prevention alone
• Never mentions when in-person care would be better

This is the screening that clinician-led services build their intake around. The point isn't the brand. The point is that the evaluationis the product. If a service treats screening as a speed bump, that's your answer. (Read next: how we compare online HRT providers.)

Are compounded “bioidentical” hormones safer if you have contraindications?

No — and no page should tell you they are. Compounded hormones are custom-mixed by a pharmacy and are notFDA-approved finished drug products, so they shouldn't be treated as automatically safer, more natural, or covered by the 2026 FDA label changes. The FDA says compounded “bioidentical” hormones are not FDA-approved and that it does not have evidence they are safer or more effective than FDA-approved hormone therapy.

This matters on a safetypage because people with risk factors are sometimes nudged toward “natural, bioidentical” compounds marketed as the gentler choice. That marketing isn't a safety guarantee.

To keep it straight:

• FDA-approved products have been reviewed by the FDA and carry standardized dosing and a risk label.
• Compounded productsare mixed for an individual prescription by a licensed compounding pharmacy. They can be a legitimate, clinician-prescribed option for some people — for example, when someone can't tolerate an ingredient in an approved product. But “compounded” is not the same as “FDA-approved,” and we won't blur the two.

Some telehealth providers say this plainly themselves. Sesame's own materials note that compounded therapy is prescribed and dispensed outside formal FDA regulation and standardization, and that studies have not shown it's safer or more effective than traditional HRT. If you have contraindications, the conservative starting point is an FDA-approved option with a clinician — not a compound chosen because a page implied it was safer.

What can you use instead if you can't take systemic HRT?

If systemic HRT isn't right for you, you usually still have options — non-hormonal prescription medicines, local vaginal therapies, and symptom-specific treatments. The best alternative depends on which symptom you most need to fix. But heads-up: some of these have their own contraindications, so “non-hormonal” doesn't automatically mean “safe for everyone.”

Cleveland Clinic lists several of these — antidepressants, gabapentin, oxybutynin, clonidine, fezolinetant, and paroxetine — as non-hormonal options for menopause symptoms.

One honest limit: non-hormonal options aren't a like-for-like swap for HRT. Some treat hot flashes but won't help vaginal dryness, bone density, or the broader symptom picture. That's exactly why it helps to get clear on which symptom you most need solved before you choose a path.

Does this page apply to testosterone or gender-affirming hormone therapy?

Only partly. This page is about menopause hormone therapy — mostly estrogen and progestogen decisions. Testosterone therapy and gender-affirming hormone therapy have different goals, different monitoring, and different contraindications, so they deserve their own pages rather than being squeezed into this one.

A few quick clarifications:

• Testosterone for menopauseis used in limited situations (often low sexual desire), needs its own monitoring, and isn't the focus here.
• Gender-affirming hormone therapy follows a different clinical pathway, with its own eligibility and assessment steps (the Endocrine Society publishes guidance for this). Don't read menopause contraindications as the rulebook for it.
• Testosterone replacement (TRT) has separate concerns — and note that in the U.S., testosterone is a Schedule III controlled substance, per the DEA, so it always requires a proper prescription and clinician oversight.

We're building dedicated pages on TRT contraindications and gender-affirming HRT contraindications — we'll link them here when they're live.

How we built and checked this page

We separated four kinds of claims — medical facts, regulatory facts, commercial facts, and our own editorial conclusions — and sourced each appropriately. Medical and regulatory facts come from the FDA, ACOG, The Menopause Society, and major medical centers; anything about specific providers is a commercial fact we re-check on a schedule.

✅ What we actually verified

• The contraindication lists, cross-checked against FDA labeling, ACOG, The Menopause Society, and clinical references
• The 2025–26 FDA label change: what was removed from the boxed warning, that the endometrial-cancer warning stayed on systemic estrogen-alone products, and which products were updated first
• The route differences (oral vs. transdermal vs. vaginal), including the 2015 meta-analysis comparing clot risk
• The vaginal-estrogen-after-breast-cancer nuance, including the aromatase-inhibitor caution
• The compounded-vs-FDA-approved distinction, including the FDA's own language and a provider's public disclosure
• The Midi insurance and availability facts (from Midi's website) and the Veozah, ospemifene, and fezolinetant safety details (from FDA labeling)

Not verified, on purpose

• We did not diagnose you. A page can't.
• We did not call any provider “safer” without a verified process.
• We did not call compounded products FDA-approved.
• We did not use patient quotes as proof that HRT is safe or effective.

Next scheduled review: July 2026 for provider details; September 2026 for medical and regulatory facts, or sooner if guidance changes.

Which menopause HRT products got updated FDA labels first?

As of the FDA's update current to February 12, 2026, six menopause hormone products were the first to get revised prescribing information — covering all four categories of menopause HRT. We pulled them together here so you can see the spread at a glance, per the FDA's product list.

The FDA has said more products are coming as additional companies submit their label changes — so if your product isn't here yet, check its current label with your clinician.

What good HRT care should feel like

A good HRT experience isn't about speed — it's about being asked the right questions and routed honestly. Patient comments can show what people value in a care experience (being listened to, being screened carefully), but they should never be read as proof that HRT is safe or effective for you.

“I felt heard and validated. I've been looking for this for a long time.”
— from a patient testimonial published on Midi Health's website

Patient comments describe one person's experience only. They are not evidence that HRT is right for you, not proof of safety, and not a guarantee of results.

HRT contraindications: frequently asked questions

What are the absolute contraindications for HRT?

The main contraindications to systemic menopause HRT are unexplained vaginal bleeding, severe active liver disease, a history of breast cancer or another estrogen-sensitive cancer, a history of stroke, heart attack, or coronary heart disease, a history of blood clots (DVT/PE/VTE), and a known high-risk clotting disorder. Some situations need specialist review rather than a simple yes or no.

Who should not take HRT?

People with a history of breast or uterine cancer, stroke, heart attack, blood clots, or liver disease are usually not routine candidates for systemic HRT without a clinician's review. ACOG lists these as situations where systemic hormone therapy is generally not recommended.

Is a family history of breast cancer a contraindication to HRT?

No. A family history is a risk factor to discuss with a clinician, but it is not the same as having had an estrogen-sensitive cancer yourself, and many people with a family history still explore HRT after a personal risk review.

Can I take HRT if I had a blood clot?

A past DVT, PE, or VTE, or a known clotting disorder, is a strong reason to get a clinician's review before systemic HRT. The route can matter — the patch carries less clot risk than the pill — but a clotting history is not a do-it-yourself decision.

Can I take HRT if I have high blood pressure?

Controlled high blood pressure is often workable with clinician review, while uncontrolled or severe high blood pressure should be addressed first. A clinician should weigh your blood pressure, heart history, age, and route options together.

Is vaginal estrogen contraindicated the same way as systemic HRT?

Not usually. Low-dose vaginal estrogen has minimal systemic absorption and is handled differently, especially when symptoms are vaginal or urinary only — but it's still an estrogen, product labels can carry warnings, and cancer survivors should involve their oncologist before using it.

Did the FDA remove HRT contraindications in 2026?

No. The 2025–26 label changes removed certain risk statements from the boxed warning, but the contraindications and the need for individual review still apply, and the endometrial-cancer warning stayed on systemic estrogen-alone products.

Are compounded hormones safer if I have contraindications?

No page should tell you that. Compounded hormones are not FDA-approved finished products and shouldn't be treated as automatically safer; the FDA says it has no evidence they are safer or more effective than FDA-approved hormone therapy.

Should I stop HRT if I think I've developed a contraindication?

Don't stop or change a prescribed medicine on your own — contact your clinician. But new bleeding, clot symptoms, chest pain, or stroke symptoms need prompt medical evaluation, so seek urgent care for those.

Can an online provider prescribe HRT if I have a contraindication?

A responsible online provider should review your case carefully, ask for more information, or route you to in-person or specialist care when needed. Sesame's public materials, for example, note that severe or complex cases may require an in-person evaluation.

Still not sure which HRT program is right for you? Take our free 60-second matching quiz— answer a few questions about your symptoms and history, and we'll point you toward the safest next step for your situation, whether that's a clinician review, a specialist, or a non-hormonal option.

Sources

1. FDA — FDA Approves Labeling Changes to Menopausal Hormone Therapy Products (fda.gov, 2026); Menopausal Hormone Therapies with Updated Prescribing Information (current to Feb 12, 2026); Menopause/ women's health topics
2. The Menopause Society — Hormone Therapy Position Statement (via The ObG Project summary) and 2025 comments on the FDA announcement
3. American College of Obstetricians and Gynecologists (ACOG) — Hormone Therapy for Menopause; Committee Opinion on estrogen route of administration and VTE risk
4. Mohammed K, et al. Oral vs Transdermal Estrogen Therapy and Vascular Events: A Systematic Review and Meta-Analysis. J Clin Endocrinol Metab. 2015 (PubMed 26544651)
5. Mayo Clinic — Hormone therapy: Is it right for you?; Cleveland Clinic — Hormone Replacement Therapy (HRT) for Menopause
6. Rethinking Menopausal Hormone Therapy — Circulation (AHA Journals) on blood-pressure threshold
7. DailyMed / FDA labeling — VEOZAH (fezolinetant) boxed warning; OSPHENA (ospemifene); estradiol vaginal insert
8. Midi Health (joinmidi.com) — availability, insurance, Medicaid/Medi-Cal and Medicare notes, patient testimonial; Sesame Care (sesamecare.com) — menopause treatment and compounded-therapy disclosure
9. DEA — Drug Scheduling (testosterone, Schedule III); Endocrine Society — Gender Dysphoria/Gender Incongruence Guideline

This page is educational research, not medical advice. Talk to a licensed clinician about your individual situation.